BRD2 and Graves disease: Adult case reports have described the onset of Graves’ disease following treatment with buserelin and/or goserelin, or during controlled ovarian stimulation (COS), which involves pharmacological evaluation of FSH and human chorionic gonadotropin (hCG) excess [6,12,13].